AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26468172 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (1mL triamcinolone acetonide 10mg/mL and 1mL lidocaine 2%)
Number of subjects: 49
Study 23104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (vitamin D 600,000 IU single intramuscular dose + calcium 75 mg/kg/day elemental calcium orally)
Number of subjects: 67
Study 23104564 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone (600,000 IU single intramuscular dose)
Number of subjects: 67
Study 23104564 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (75 mg/kg/day elemental calcium orally)
Number of subjects: 67
Study 21503388 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 372
Study 21503388 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 372
Study 21503388 — intervention group
Group type: COMPARATOR
Intervention: Clinical treatment
Number of subjects: 372
Study 19839894 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocanalicular intubation
Number of subjects: 54
Study 19839894 — intervention group
Group type: COMPARATOR
Intervention: Bicanalicular intubation
Number of subjects: 54
Study 16988850 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin plus glyceryl trinitrate (Group A)
Number of subjects: 30
Study 16988850 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin plus placebo paste (Group B)
Number of subjects: 30
Study 12505939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (EC group)
Number of subjects: 64
Study 12505939 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (EM group)
Number of subjects: 64
Study 12505939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (YC group)
Number of subjects: 64
Study 12505939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (YC‐HP group)
Number of subjects: 64
Study 12505939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (EC‐LP group)
Number of subjects: 64
Study 11272970 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI)
Number of subjects: 0
Study 11272970 — intervention group
Group type: COMPARATOR
Intervention: Intermittent flushing (IF)
Number of subjects: 0
Study 8894432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate cream, 1 percent (monotherapy)
Number of subjects: 0
Study 8894432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with oxiconazole nitrate cream, 1 percent and fluticasone propionate cream, 0.05 percent
Number of subjects: 0
Study 8894432 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 1899409 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 145
Study 1899409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 6349785 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (80 mg/m2/day IV X 3 and repeat every 8 weeks)
Number of subjects: 626
Study 6349785 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (125 mg/m2/day orally X 1 and repeat every 8 weeks) + DTIC (150 mg/m2/day IV X 5 and repeat every 4 weeks)
Number of subjects: 626
Study 6349785 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher radiation dose (7000 rad/8-9 weeks)
Number of subjects: 626
Study 6349785 — intervention group
Group type: COMPARATOR
Intervention: Control radiation (6000 rad/6-7 weeks to whole brain)
Number of subjects: 626
Study 31931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) usage among GPs
Number of subjects: 286
Study 31931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for fracture diagnosis
Number of subjects: 286
Study 31931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about ultrasonographic fracture diagnosis
Number of subjects: 286
Study 31931750 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of US and conventional X-rays
Number of subjects: 286
Study 31931750 — intervention group
Group type: COMPARATOR
Intervention: Knowledge and usage of US for fracture diagnosis
Number of subjects: 286
Study 30781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect2Scratch game training
Number of subjects: 33
Study 30781936 — intervention group
Group type: COMPARATOR
Intervention: Therapist-based training
Number of subjects: 33
Study 28360825 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplement (OS)
Number of subjects: 25
Study 28360825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taste matched)
Number of subjects: 25
Study 25930208 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1615
Study 25930208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1615
Study 23999845 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-focused group intervention led by peer counselors and professional counselors
Number of subjects: 82
Study 21807562 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203
Study 21807562 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection
Number of subjects: 203
Study 21807562 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 203
Study 19567163 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoharringtonine (HHT) 1.5 mg/m² by continuous daily infusion for seven to nine days every four weeks
Number of subjects: 106
Study 19567163 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha (IFN‐alpha)
Number of subjects: 106
Study 19567163 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide
Number of subjects: 106
Study 19567163 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT as salvage treatment for patients who failed IFN‐alpha
Number of subjects: 106
Study 17012656 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised outcome assessment (monthly postal questionnaires and 3-monthly feedback)
Number of subjects: 160
Study 17012656 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 160
Study 15007003 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin use
Number of subjects: 0
Study 15007003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm (SR)
Number of subjects: 0
Study 15007003 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 0
Study 11054217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic compression bandages (Unna boots on the lower leg, adhesive bandages on the thigh)
Number of subjects: 45
Study 11054217 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh‐length compression stockings, class II
Number of subjects: 45
Study 11054217 — intervention group
Group type: COMPARATOR
Intervention: Bed rest with no compression
Number of subjects: 45
Study 9507837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9507837 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg phentolamine
Number of subjects: 44
Study 9507837 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine
Number of subjects: 44
Study 9507837 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg phentolamine
Number of subjects: 44
Study 8042808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg.kg‐1)
Number of subjects: 30
Study 8042808 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg.kg‐1)
Number of subjects: 30
Study 3055819 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel
Number of subjects: 22
Study 3055819 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 22
Study 29543547 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC® with citrate-bicarbonate buffer (Group I)
Number of subjects: 900
Study 29543547 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC® alone without buffer (Group II)
Number of subjects: 900
Study 29543547 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC® mixed with buffer (Group III)
Number of subjects: 900
Study 29543547 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 900
Study 28415065 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized vibration (30 Hz) to 4 selected lower-body areas
Number of subjects: 21
Study 28415065 — intervention group
Group type: COMPARATOR
Intervention: Moderately low-resistance stationary cycling (70 rpm)
Number of subjects: 21
Study 26429297 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide
Number of subjects: 252
Study 26429297 — intervention group
Group type: COMPARATOR
Intervention: Busulfan plus fludarabine
Number of subjects: 252
Study 23358639 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based antiretroviral therapy (ART)
Number of subjects: 0
Study 23358639 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor-based ART
Number of subjects: 0
Study 21660428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 70
Study 21660428 — intervention group
Group type: COMPARATOR
Intervention: Social Recreational (SR)
Number of subjects: 70
Study 18794000 — intervention group
Group type: EXPERIMENTAL
Intervention: Current techniques available in the management of hemorrhoids and anal fissures
Number of subjects: 0
Study 16550052 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Number of subjects: 0
Study 16550052 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 0
Study 11834139 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ingestion of black tea (5 cups per day for 4 weeks)
Number of subjects: 21
Study 11834139 — intervention group
Group type: COMPARATOR
Intervention: Hot water ingestion (control)
Number of subjects: 21
Study 10825861 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush bristle arrangement
Number of subjects: 0
Study 10825861 — intervention group
Group type: COMPARATOR
Intervention: Conventional V-shaped toothbrush
Number of subjects: 0
Study 10825861 — intervention group
Group type: COMPARATOR
Intervention: Flat-headed toothbrush
Number of subjects: 0
Study 7584704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol at a dose of 100 ng/kg/day
Number of subjects: 8
Study 7584704 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol via adhesive skin patch at 0.0125 mg/kg/day
Number of subjects: 8
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol (long-acting)
Number of subjects: 11
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol + 120 mg ISDN (sustained-release)
Number of subjects: 11
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol + 120 mg diltiazem (sustained-release)
Number of subjects: 11
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol + 10 mg nisoldipine
Number of subjects: 11
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol + 120 mg ISDN + 120 mg diltiazem
Number of subjects: 11
Study 1980660 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol + 120 mg ISDN + 10 mg nisoldipine
Number of subjects: 11
Study 371663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 28
Study 371663 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 6841564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (3 days treatment)
Number of subjects: 7
Study 6841564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30085178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SP strain vaccine
Number of subjects: 1080
Study 30085178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SP strain vaccine
Number of subjects: 1080
Study 30085178 — intervention group
Group type: COMPARATOR
Intervention: High-dose S79 vaccine
Number of subjects: 1080
Study 30085178 — intervention group
Group type: COMPARATOR
Intervention: Low-dose S79 vaccine
Number of subjects: 1080
Study 30085178 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1080
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable state
Number of subjects: 498
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation
Number of subjects: 498
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up 4 weeks after exacerbation
Number of subjects: 498
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe exacerbation
Number of subjects: 498
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M, C4Ma3, C4M2
Number of subjects: 498
Study 29966667 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the biomarkers
Number of subjects: 498
Study 27935886 — intervention group
Group type: EXPERIMENTAL
Intervention: Detralex (micronized purified flavonoid fraction) at a daily dose of 1,000 mg for 2 weeks prior to sclerotherapy and for at least 2 months after the procedure
Number of subjects: 60
Study 27935886 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no drug)
Number of subjects: 60
Study 24586327 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention (community-based support program)
Number of subjects: 7169
Study 24586327 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (no intervention)
Number of subjects: 7169
Study 22782376 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 65
Study 22782376 — intervention group
Group type: COMPARATOR
Intervention: Modified endoscopic plantar fasciotomy
Number of subjects: 65
Study 21048483 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeSlips intervention (twice-weekly for 6 weeks)
Number of subjects: 56
Study 21048483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 17237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone for stages I and IIa
Number of subjects: 0
Study 17237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (CT) or chemoradiation (CRT) followed by surgery for stage IIb
Number of subjects: 0
Study 17237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant CT or CRT followed by surgery for locally advanced adenocarcinomas (stage III)
Number of subjects: 0
Study 17237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive CRT for locally advanced squamous cell carcinomas (stage III)
Number of subjects: 0
Study 17237006 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant surgery in experienced centres for selected patients
Number of subjects: 0
Study 15708211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences with semantically complex verbs (e.g., causatives)
Number of subjects: 140
Study 15708211 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically and morphologically complex verbs
Number of subjects: 140
Study 12109920 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 825
Study 12109920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 10391659 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSQOLI
Number of subjects: 0
Study 10391659 — intervention group
Group type: COMPARATOR
Intervention: EORTC QLQ-C30
Number of subjects: 0
Study 10391659 — intervention group
Group type: COMPARATOR
Intervention: QLM-P14
Number of subjects: 0
Study 7751684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal bovine parainfluenza virus type 3 (BPIV‐3) vaccine
Number of subjects: 92
Study 7751684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 1968773 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 90
Study 1968773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 90
Study 1968773 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 90
Study 1968773 — intervention group
Group type: COMPARATOR
Intervention: Adrenergic agonists (Clonidine and Guanfacine)
Number of subjects: 90
Study 107908 — intervention group
Group type: EXPERIMENTAL
Intervention: Protirelin
Number of subjects: 0
Study 107908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31143445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements with added high-dose vitamins and minerals (LNS-VM)
Number of subjects: 1752
Study 31143445 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 1752
Study 29735881 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream plus Vapocoolant spray
Number of subjects: 90
Study 29735881 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine spray
Number of subjects: 90
Study 29735881 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream only
Number of subjects: 90
Study 26686336 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT study
Number of subjects: 2381
Study 26686336 — intervention group
Group type: EXPERIMENTAL
Intervention: PET study
Number of subjects: 2381
Study 26686336 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality score
Number of subjects: 2381
Study 26686336 — intervention group
Group type: COMPARATOR
Intervention: Adherence to best practices
Number of subjects: 2381
Study 26686336 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices
Number of subjects: 2381
Study 24934986 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus rifampicin for 6 weeks and streptomycin for the first 7 days
Number of subjects: 144
Study 24934986 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus rifampicin for 8 weeks and streptomycin for 7 days
Number of subjects: 144
Study 22335487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 20
Study 22335487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20678684 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 7.5 mg alone (treatment A)
Number of subjects: 12
Study 20678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg with zibotentan 10 mg once daily (treatment B)
Number of subjects: 12
Study 20678684 — intervention group
Group type: COMPARATOR
Intervention: Zibotentan 10 mg once daily
Number of subjects: 12
Study 17426305 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended program (24 hours of education, 28 hours of support groups)
Number of subjects: 216
Study 17426305 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed strategy (16 hours of education, 6 hours of support groups)
Number of subjects: 216
Study 15711832 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 900 mg single oral dose
Number of subjects: 0
Study 15711832 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal 600 mg once daily for 14 days
Number of subjects: 0
Study 12742469 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus plus mycophenolate mofetil (group A)
Number of subjects: 180
Study 12742469 — intervention group
Group type: COMPARATOR
Intervention: sirolimus plus cyclosporine (group B)
Number of subjects: 180
Study 10396905 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet Networks (WN) single-sweep analysis
Number of subjects: 50
Study 10396905 — intervention group
Group type: COMPARATOR
Intervention: Averaged ERP analysis
Number of subjects: 50
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett's oesophagus patients (n = 104)
Number of subjects: 641
Study 7475821 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 537)
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 59
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal bleeding
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous colonic investigation
Number of subjects: 641
Study 7475821 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete colonoscopy
Number of subjects: 641
Study 2137653 — intervention group
Group type: EXPERIMENTAL
Intervention: RATG (polyclonal)
Number of subjects: 82
Study 2137653 — intervention group
Group type: COMPARATOR
Intervention: OKT3 (monoclonal)
Number of subjects: 82
Study 6986236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clocortolone pivalate 0.1 percent cream
Number of subjects: 100
Study 6986236 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream base
Number of subjects: 100
Study 31314651 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Occupation Executive Training (POET)
Number of subjects: 72
Study 30694582 — intervention group
Group type: EXPERIMENTAL
Intervention: HepCATT intervention (placement of a half-time facilitator in clinics for 12 months)
Number of subjects: 0
Study 30694582 — intervention group
Group type: EXPERIMENTAL
Intervention: HepCATT intervention
Number of subjects: 0
Study 30694582 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no intervention)
Number of subjects: 0
Study 30694582 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 0
Study 29561497 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.50 D add Biofinity Multifocal 'D' MFCLs
Number of subjects: 294
Study 29561497 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected MFCLs
Number of subjects: 294
Study 29561497 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopic pupil size
Number of subjects: 294
Study 27283929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin
Number of subjects: 20
Study 27283929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24284781 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine
Number of subjects: 193
Study 24284781 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 193
Study 22422428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Geriatric Unit (CGU)
Number of subjects: 96